Ophthalmology submission guide

Best Ophthalmology Journals for Manuscript Submission in 2026

The best ophthalmology journal in 2026 depends on the disease, manuscript type, and audience. Use the three groups below to compare manuscript fit with the 2026 Impact Factor, JCR quartile, 2025 publication volume, and qualified PubMed submission-to-acceptance timing.

This guide compares the 2026 JIF with 2025 OpenAlex publication output. Journal metrics provide context, while manuscript fit and current author instructions should drive the submission decision.

Published June 25, 2026 · Updated June 26, 2026 · Journal Submission Guides

How to select a ophthalmology journal

Start with the disease, manuscript type, and readers who should use the result. A broad clinical cohort, a subspecialty surgery study, and a mechanistic visual science paper can need different journals even when all address the same eye disease.

Check audience fit explicitly across retina, glaucoma, cornea and anterior segment, imaging and AI, surgery, visual science, and population eye health.

Treat the three groups as an editorial fit shortlist, not a ranking or prediction of acceptance. Confirm the live aims, article type, and author instructions before submitting.

Manuscript type matrix

Start with the manuscript's main contribution, then compare audience and article-type fit before using journal metrics.

Manuscript typePrioritizeAvoid when
Broad clinical cohortsPrioritize: A clinical ophthalmology readership that manages the diseases, interventions, and outcomes represented in the cohort.Avoid when: The result is narrowly subspecialty-specific or descriptive without a conclusion that travels beyond one local practice.
Randomized/interventionalPrioritize: A journal reaching clinicians who can act on the intervention, with an article type suited to the trial design and reporting standard.Avoid when: Registration, power, comparator choice, follow-up, or outcome definitions do not support the claimed practice implication.
RetinaPrioritize: A retinal audience aligned with the disease, imaging modality, treatment, vitreoretinal surgery, and patient outcome.Avoid when: Retina is only a secondary subgroup or the main contribution is a general method intended for multiple subspecialties.
GlaucomaPrioritize: Readers focused on glaucoma diagnosis, progression, imaging, medical treatment, surgery, and longitudinal outcomes.Avoid when: Glaucoma is incidental to a broader imaging or population-health question.
Cornea/anterior segmentPrioritize: A cornea and anterior-segment audience matched to ocular surface disease, transplantation, refractive or cataract surgery, and outcomes.Avoid when: The anterior-segment population is a convenience sample rather than the paper's central clinical audience.
Imaging/AIPrioritize: Journals that reach the intended clinical or technical users and expect rigorous validation across relevant devices and populations.Avoid when: The model lacks external validation, clinically meaningful comparison, transparent reporting, or a credible path to use.
Visual science/basic mechanismsPrioritize: A mechanistic or translational readership aligned with the experimental model, visual function, ocular tissue, and biological question.Avoid when: The study is purely descriptive or makes clinical claims without a demonstrated translational bridge.
Population eye healthPrioritize: Readers working in epidemiology, prevention, access, policy, health services, disparities, and implementation of eye care.Avoid when: A local prevalence estimate or service description lacks a broader inference, comparison, or actionable eye-health implication.

Reach journals

Consider these when the evidence is rigorous and the conclusion matters across ophthalmic practice or population eye health. A broad readership is a fit signal, not evidence of easier acceptance.

OPHTHALMOLOGY

Elsevier BV

Subscription or hybrid
2026 Impact Factor
10.9
JCR quartile
Q1
2025 publication volume
374
Median submission-to-acceptance
65.5 days
n=100 · 100% coverage

Suitable for

  • Practice-changing trials and comparative studies
  • Large clinical cohorts and outcomes research
  • Validated imaging and health-services evidence

Why it may fit

Practice-changing clinical ophthalmology, trials, large cohorts, imaging, and health-services evidence.

Caution

Broad clinical importance and rigorous validation are expected.

JAMA Ophthalmology

American Medical Association

Subscription or hybrid
2026 Impact Factor
10.5
JCR quartile
Q1
2025 publication volume
303
Median submission-to-acceptance
Not enough public date data

Suitable for

  • Clinically consequential eye research
  • Epidemiology and population eye health
  • Policy and evidence affecting patient care

Why it may fit

Clinically consequential eye research, epidemiology, policy, and evidence affecting patient care.

Caution

Frame the result for broad clinical and public-health relevance.

Subscription or hybrid
2026 Impact Factor
4.7
JCR quartile
Q1
2025 publication volume
586
Median submission-to-acceptance
100.5 days
n=96 · 96% coverage

Suitable for

  • Retina, glaucoma, and cornea studies
  • Ophthalmic surgery and clinical outcomes
  • Clinically relevant imaging research

Why it may fit

Clinical studies across retina, glaucoma, cornea, surgery, imaging, and outcomes.

Caution

Confirm the accepted study and article type in current instructions.

Subscription or hybrid
2026 Impact Factor
4.5
JCR quartile
Q1
2025 publication volume
249
Median submission-to-acceptance
152 days
n=99 · 99% coverage

Suitable for

  • International clinical and surgical studies
  • Epidemiology and population eye health
  • Translational ophthalmology with clinical relevance

Why it may fit

International clinical, surgical, epidemiologic, and translational ophthalmology.

Caution

The conclusion should matter beyond a narrow local practice pattern.

Strong-match journals

These can be the strongest destination when a retina, visual science, clinical-translational, or data-driven readership matches the paper more precisely. A focused scope is not an easier acceptance path.

Subscription or hybrid
2026 Impact Factor
5.9
JCR quartile
Q1
2025 publication volume
286
Median submission-to-acceptance
40 days
n=100 · 100% coverage

Suitable for

  • Retinal disease and treatment studies
  • Retinal imaging and biomarkers
  • Vitreoretinal surgery, trials, and real-world outcomes

Why it may fit

Retinal disease, imaging, vitreoretinal surgery, trials, and real-world retina outcomes.

Caution

Retina must be the primary audience rather than a secondary analysis.

2026 Impact Factor
5.5
JCR quartile
Q1
2025 publication volume
834
Median submission-to-acceptance
Not enough public date data

Suitable for

  • Mechanisms of normal and abnormal visual function
  • Translational eye and vision research
  • Quantitative imaging and structure-function studies

Why it may fit

Mechanistic, translational, imaging, and quantitative vision research.

Caution

Purely descriptive clinical series may need a clinical journal.

Subscription or hybrid
2026 Impact Factor
5.1
JCR quartile
Q1
2025 publication volume
187
Median submission-to-acceptance
127 days
n=97 · 97% coverage

Suitable for

  • Clinical ophthalmology with practice implications
  • Translational eye research
  • Imaging and experimental findings linked to patient care

Why it may fit

Clinical and translational eye research with clear implications for ophthalmic practice.

Caution

Connect laboratory or imaging findings to the clinical audience.

Open access
2026 Impact Factor
5.0
JCR quartile
Q1
2025 publication volume
338
Median submission-to-acceptance
133 days
n=99 · 99% coverage

Suitable for

  • Preclinical development
  • Phase 1–2 clinical trials
  • Laboratory and ophthalmology informatics studies

Why it may fit

Open-access preclinical, early-phase clinical, laboratory, informatics, and data-driven ophthalmic science.

Caution

Later-phase or broadly practice-changing clinical studies may fit a more general clinical journal; verify current indexing, fees, and reporting requirements.

Broader-scope journals

These journals can fit mechanistic, technological, open clinical, or international work when their audience and article type align. Broader scope does not mean easier acceptance; evidence quality and editorial fit still matter.

Subscription or hybrid
2026 Impact Factor
3.1
JCR quartile
Q2
2025 publication volume
498
Median submission-to-acceptance
109 days
n=100 · 100% coverage

Suitable for

  • Cellular and molecular eye research
  • Ocular physiology and disease mechanisms
  • Preclinical models with mechanistic depth

Why it may fit

Cellular, molecular, physiological, and preclinical mechanisms of eye disease.

Caution

Human clinical outcome papers without mechanistic depth may not fit.

Translational Vision Science & Technology

Association for Research in Vision and Ophthalmology

Open access
2026 Impact Factor
2.7
JCR quartile
Q2
2025 publication volume
392
Median submission-to-acceptance
Not enough public date data

Suitable for

  • Ophthalmic imaging and visual technology
  • Devices and quantitative clinical tools
  • Validated AI with a path to clinical application

Why it may fit

Visual technology, imaging, devices, AI, and translation toward clinical use.

Caution

Demonstrate validation and a credible path to clinical application.

2026 Impact Factor
2.7
JCR quartile
Q2
2025 publication volume
135
Median submission-to-acceptance
143 days
n=98 · 98% coverage

Suitable for

  • Open clinical and surgical ophthalmology
  • Epidemiology and population eye health
  • Health-services and implementation research

Why it may fit

Open clinical, epidemiologic, surgical, and health-services eye research.

Caution

Open access and publication volume do not imply easier acceptance.

Subscription or hybrid
2026 Impact Factor
2.8
JCR quartile
Q2
2025 publication volume
337
Median submission-to-acceptance
139 days
n=100 · 100% coverage

Suitable for

  • Clinical ophthalmology across subspecialties
  • Clinically relevant experimental research
  • International cohorts and outcomes studies

Why it may fit

Broad clinical and experimental ophthalmology across subspecialties.

Caution

Show why the result matters to an international ophthalmic readership.

Journals receiving a first JIF in 2026

Explore newer metric entrants separately, then return to manuscript fit when building the final submission shortlist.

See the ophthalmology first-JIF analysis

Test the shortlist against your research

Compare manuscript fit with AI or examine the literature around your research topic in PubMed.

Methodology and limits

Broader-scope does not mean easy acceptance. There is no comprehensive acceptance-rate data for these journals, and the metrics on this page do not predict acceptance.

Publication volume uses OpenAlex works from the complete 2025 calendar year. OpenAlex works are not submissions or acceptances, so output describes publishing scale rather than editorial selectivity.

Timing uses qualified PubMed received-to-accepted date pairs from the fixed 2024–2025 window. It is a historical median, not a forecast. Missing date data is not evidence of speed, and unqualified journals are shown as “Not enough public date data.”

Confirm each journal's current scope, article types, author instructions, indexing, fees, and policies before submission.

Frequently asked questions

Should I choose a general ophthalmology journal or a subspecialty journal?

Choose the audience that most needs the result. A general journal can suit evidence with broad clinical or public-health implications, while a subspecialty journal is often the better match when the disease, procedure, imaging method, and practical implications are concentrated in retina, glaucoma, cornea, or another focused practice.

Does higher publication volume mean a journal is easier to enter?

No. The 2025 OpenAlex publication volume describes recent output, not an acceptance rate or editorial threshold. Use it to understand publishing scale only, then evaluate scope, article type, evidence quality, and audience fit.

What does the PubMed submission-to-acceptance timing mean?

The timing is a median calculated only for journals with qualified coverage of paired received and accepted dates in PubMed records. It is descriptive historical context, not a promise for a new submission or a substitute for the journal's current guidance.

How does the first-JIF analysis complement this guide?

The linked first-JIF analysis examines ophthalmology journals receiving a first Journal Impact Factor in the 2026 release. Use it to explore newer metric entrants, then return here to compare established shortlist options by manuscript fit.

Related Articles

Take the next research step

Compare manuscript fit with AI or examine the literature around your research topic in PubMed.

Canonical article: https://www.journalmetrics.org/blog/best-ophthalmology-journals